Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05473910 · ClinicalTrials.gov registry record · Phase 1
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
A Phase 1 study of Myelodysplastic Syndromes and AML, sponsored by TScan Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 15
- Study locations
NCT05473910: Recruiting Phase 1 study of Myelodysplastic Syndromes and AML, sponsored by TScan Therapeutics.
NCT05473910 is a Phase 1 study of Myelodysplastic Syndromes and AML that is actively recruiting participants, run by TScan Therapeutics. The registered enrollment target is 75 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (74% lower). The trial reports 15 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05473910, a Phase 1 study of Myelodysplastic Syndromes and AML, is actively recruiting participants, sponsored by TScan Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD
Primary Outcome
Number of DLTs observed in patients compared to the control arm
Conditions Studied
Interventions
- OTHER Control
- DRUG SOC + TSC-100
- DRUG SOC + TSC-101
Study Locations (15)
New York
- Columbia University - New York
- Mount Sinai - New York
Texas
- Baylor University Medical Center - Dallas
- MD Anderson - Houston
California
- City of Hope - Duarte
Connecticut
- Yale - New Haven
Florida
- Memorial Healthcare System - Hollywood
Georgia
- Northside Hospital - Atlanta
Maryland
- John Hopkins University - Baltimore
Massachusetts
- Mass General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What NCT05473910 shows while recruiting
NCT05473910 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (74% lower).
The record links to 3 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 3 interventions - of which Control is the first listed.
NCT05473910 lists 15 locations in 13 states (New York, Texas, California).
Frequently Asked Questions
What is clinical trial NCT05473910 about?
NCT05473910 is a clinical study titled "A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation". This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AM...
What is the current status of trial NCT05473910?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2022-11-01. Estimated completion is 2026-06.
What conditions does trial NCT05473910 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, AML, ALL, Adult.
What interventions are being tested in trial NCT05473910?
The interventions under investigation include: Control (OTHER), SOC + TSC-100 (DRUG), SOC + TSC-101 (DRUG).
Who is sponsoring clinical trial NCT05473910?
This trial is sponsored by TScan Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05473910 being conducted?
This trial has 15 study locations across California, Connecticut, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05473910's enrollment target sits among peer trials
75 70th of 173 higher than 102 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
RECRUITING · Phase 1
-
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI